NovaBridge Biosciences NBP
NASDAQ NBP
$1.80 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

NovaBridge Biosciences (NBP) Change in Accured Expenses (2019 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Change in Accured Expenses of $10.7 million for Q4 2025, up 423.15% year-over-year from $2.0 million in Q4 2024, and up 23.96% quarter-over-quarter from $8.6 million in Q3 2025.

Analysis

NovaBridge Biosciences (NBP) Change in Accured Expenses (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Change in Accured Expenses for 4 consecutive years, with $10.7 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Change in Accured Expenses rose 423.15% year-over-year to $10.7 million; the TTM figure through Dec 2025 stood at $15.8 million (down 38.33% YoY), while the FY2025 annual figure was $18.1 million, up 8588.73% from the prior year.
  • Change in Accured Expenses climbed to $10.7 million in Q4 2025 per NBP's latest filing, from $8.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $10.7 million in Q4 2025 and bottomed at -$3.3 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 11.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 55.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 212.44 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 61.62 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 68.82 Mn
10 NovaBridge Biosciences 197.68 Mn 197.68 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 10.71 Mn
Sep 30, 2025 8.64 Mn
Dec 31, 2024 -3.31 Mn
Sep 30, 2024 -240,000.00
Dec 31, 2020 28.87 Mn
Sep 30, 2020 284,190.23
Dec 31, 2019 22.16 Mn